Prior to BMS, Karina was at Merck & Co., where she held positions of increasing responsibility within Clinical Pharmacogenomics and Clinical Specimen Management. Most recently, she was the head of Global Genomic Policy, Process and Compliance (GPPC), where was responsible for evaluating the impact of global genomic and biospecimen policies and laws/regulations on Merck’s research programs; developing Merck policies, processes and consent related to genomics and biobanking; and ensuring the compliant use of biospecimens. In this role, Karina also implemented routine genotyping of patients participating in Merck’s clinical trials to identify genetic predictors of drug response. She also served as the Merck representative to the Roundtable on Genomics and Precision Health of the National Academies of Sciences, Engineering and Medicine.
Karina completed an internship in Clinical Psychology at Nassau University Medical Center and a postdoctoral fellowship in Clinical Psychopharmacology in the Department of Psychiatry at Rutgers University – Robert Wood Johnson Medical School. She holds a PhD in Clinical Psychology from St. John’s University and a B.A. in Psychology and French from New York University.
Ph. D. 1987, University of Aberdeen, Scotland, (Pharmacology/Biochemistry).
B.Sc. (Hons) 1983, University of Wales, Cardiff College, (Biochemistry).
Peter’s expertise is in the strategic development, analysis and use, of pharmacogenetic and pharmacogenomic data for decision making in clinical and preclinical drug development. Peter’s achievements and focus include: identification and validation of genomic biomarkers, implementation of in life genotyping pipelines, development of ethical processes and procedures to protect privacy and collect clinical samples, globally, for genomic research, generation of data for regulatory filings and drug labels.
Peter has collaborated with many functional groups (clinical, discovery, regulatory, legal and privacy) in and across most major therapeutic areas (Oncology, Infectious Disease, Cardiovascular, Diabetes and Neuroscience), to enable integration and application of pharmacogenomics. In addition, Peter has developed large strategic external relationships with academic centers and biotechnology companies to promote R&D, as well as contributed to multiple pre-competitive consortia programs and trade organizations to promote education and knowledge of pharmacogenetics: iPWG, SAEC, ACRG, PhRMA, EFPIA. Peter has over twenty years of experience at Merck & Co., Inc. and Bristol Myers Squibb which has led to numerous publications and patents.